|Year : 2021 | Volume
| Issue : 4 | Page : 278-282
Evidence revealing the role of T cell regulators (Tregs) in periodontal diseases: A review
Paavai Ilango1, Dhanapriya Kumar1, Arulpari Mahalingam2, Abirami Thanigaimalai1, Vineela Katam Reddy3
1 Department of Periodontics, Priyadarshini Dental College and Hospital, Thiruvallur, India
2 Department of Pedodontics, Thai Moogambigai Dental College and Hospital, Chennai, Tamil Nadu, India
3 Department of Periodontics, Indira Gandhi Dental College and Hospital, Puducherry, India
|Date of Submission||28-Apr-2020|
|Date of Decision||19-Dec-2020|
|Date of Acceptance||26-Jan-2021|
|Date of Web Publication||01-Jul-2021|
Priyadarshini Dental College and Hospital, No. 1. V. G. R Gardens, V. G. R. Nagar, Pandur, Thiruvallur - 631 203, Tamil Nadu
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Periodontitis is an inflammatory disease of the periodontium, which is a reflection of the overgrowth of oral commensals. This alteration in the oral microbiota initiates inflammation of the gingiva, which when left untreated, terminates with the resorption of the alveolar bone that may lead to a poor and hopeless prognosis. With upcoming trends in modulating the host's immunity, the role of regulatory T-cells has gained importance. These T-cells defend against inflammation and autoimmunity as they suppress both. However, in both the conditions, the regulatory cells are invariably reduced in number. Novel methods to enhance the function of Tregs have made their way in dentistry, as a promising approach to cure periodontitis. This article discusses various significant tests and trials of Tregs in the recent years.
Keywords: Immunity, immuno-modulation, periodontitis, regulatory T-cells, Treg cell therapy
|How to cite this article:|
Ilango P, Kumar D, Mahalingam A, Thanigaimalai A, Reddy VK. Evidence revealing the role of T cell regulators (Tregs) in periodontal diseases: A review. J Indian Soc Periodontol 2021;25:278-82
|How to cite this URL:|
Ilango P, Kumar D, Mahalingam A, Thanigaimalai A, Reddy VK. Evidence revealing the role of T cell regulators (Tregs) in periodontal diseases: A review. J Indian Soc Periodontol [serial online] 2021 [cited 2021 Jul 24];25:278-82. Available from: https://www.jisponline.com/text.asp?2021/25/4/278/319657
| Introduction|| |
Periodontium is a complex structure comprising of the gingiva, the alveolar bone, the periodontal ligament, and the cementum. Being amply nourished by blood, it has certain protective features such as keratinized mucosa and gingival crevicular fluid, to defend it from any sort of thermal, chemical, traumatic, or infectious insults. Despite these barriers, they are prone for periodontitis primarily due to poor oral hygiene, influenced by genetic, environmental, and systemic risk factors.
Periodontitis begins as an inflammation of the gingiva as a response to bacteria. A healthy oral microbiota has predominantly Gram positive bacteria, while in periodontitis, Gram negative bacteria predominate. A healthy periodontium resolves the inflammation by neutralizing the pathogen, whereas a compromised periodontium fails to do the same. According to specific plaque hypothesis, the pathogenicity of the bacteria influences periodontitis, more than the quantity of the bacteria. In accordance with this, there are four keystone perio pathogens namely Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Tannerella forsythensis, and Treponema denticola., The current research states that dysbiosis, as a result of these keystone pathogens, is primarily responsible for periodontitis (polymicrobial synergy dysbiosis model) and the vice versa too are hypothesized (inverted model).,
The gingiva and its defense mechanisms play a vital role in imparting immunity against bacterial colonization by preventing the breach of pathogens into the periodontium, and by the secretion of immunobiological components. In addition, the physiological inflammatory response is initiated through a series of cellular and molecular networks framed by the epithelial cells, phagocytes, and complementary cascades. However, when the inflammation exceeds the physiological limits, T-cells, B cells, immunoglobulins, and other molecules play a role in presenting the antigen. The activated acquired immunity with a help of a variety of biological mediators curb the inflammatory reactions by eliminating the pathogens. Thus, several pro-and anti-inflammatory mediators are triggered. When pro-inflammatory responses supersede the anti-inflammatory responses, immune tolerance arises.
| T-Cell and its Subsets|| |
Based on function, T-cells are classified as the helper T-cells, killer T-cells, and memory T-cells, and also classified as CD4 and CD8 cells, considering their surface expression. The CD8 T-cells are the immune effector cells and are also called the cytotoxic T-cells, while CD4 T-cells are the helper cells (Th). Based on the cytokine production, they are further grouped [Figure 1] into subsets as Th1, Th2, Th17, and Tregs. When the naive CD4 T-cells are encountered by the antigen presenting cells, they are differentiated into one of the subsets by producing the characteristic cytokines. While Th1 subsets impart a cell-mediated pro-inflammatory response, the Th2 subsets impart an antibody-mediated anti-inflammatory response. On the other hand, the Th17 (the effectors) and Treg (the regulators) subsets have a pivotal antagonistic role.
|Figure 1: Development of T cells. Th – T helper cells; Treg – T regulators; T cell – Thymus cell; B cell – Bursa of fabricius cell; CD4 – Cluster of Differentiation 4; CD8 – cluster of Differentiation 8; nTREG – Naturally occurring regulatory T cells; iTREG – Induced regulatory T cells|
Click here to view
Under noninflammatory healthy conditions, the homeostasis is maintained between the host and the commensal bacteria in the periodontium by the generation of regulatory T-cells. The antigen presenting cells favor the activation of Th2 cells that further trigger anti-inflammatory reactions. When dysbiosis occurs, they favor the activation of Th1 cells thereby promoting pro-inflammatory processes resulting in tissue damage.
| Regulatory T-Cells|| |
Tregs are polarized subpopulation of T lymphocytes regularizing immune activation and immune tolerance. They are characterized by the expression of Forkhead Box Protein 3 (foxP3) gene, which is potential enough to suppress the pro-inflammatory cytokines. Tregs are of two types [Figure 1] namely, natural Tregs or nTregs (CD4+ CD25+ FoxP3+ cells) and induced Tregs or iTregs. The natural naive Tregs, which originates and matures from the thymus (intrathymic Tregs) produce a series of anti-inflammatory cytokines. On the contrary, the maturation of iTregs occurs peripherally. The iTregs are further grouped as Tr1 subset and Th3 subset based on their pattern of cytokine production. The Tr1 subset produces interleukin 10 (IL-10) and suppresses the Th1-mediated responses and the Th3 subset produces transforming growth factor beta (TGF-β) and has a regulatory function.
It was in the 1970s, where a suppressive subpopulation of T lymphocytes was suggested in animal models. However, in 1995, Shimon Sakaguchi distinguished the suppressive subsets from regulatory subsets which were characterized as CD4 T cells that expressed both IL2Rαchain and CD25. The suppressor subsets were then characterized to be self-reactive and were responsible for the development of autoimmune and inflammatory diseases. Since then, Tregs have been through various bioassays and trials and their functions diversified with every discovery.
Their role in immune reactions
The paramount function of CD4+ CD25+ foxP3+ regulatory T-cells is to curtail the activation and the production of pro-inflammatory cytokines of the effector cells [Figure 2]. Besides the natural Tregs, the peripheral nonlymphoid tissue Tregs are found in the visceral adipose tissues, skeletal and cardiac muscles, mucosal interface, and hair follicles, that are all responsible for maintaining host-microbe homeostasis.,
|Figure 2: Treg activation , anti-inflammatory cytokine production and downregulation of pro-inflammatory cytokine. Th – T helper; TGF-β- Transforming growth factor β; IL-17- Interleukin 17; CTLA- Cytotoxic T lymphocyte associated molecule; TREG – Regulatory T cells; CD – Cluster of Differentiation ; IL – Interleukins; TH – T helper cells; ALP – Alkaline phosphatase; TGFB - Transforming growth factor beta|
Click here to view
| Tregs in Periodontitis|| |
Tregs are characterized by the expression of the phenotypic markers such as transcription factor forkhead box P3 (FOXp3), CD103, glucocorticoid-inducible TNF receptor (GITR), inhibitory molecule cytotoxic T-lymphocyte-associated molecule 4 (CTLA-4), and cell-surface TGF-β1. Immunohistology, flow cytometry, and molecular analyses characterized the presence of these markers in periodontal tissues. TGF-β1 and the CTLA-4 were known to abate the progression of periodontitis.
However, the RANKL inducing Th17 cells were also found to exceed in number, exacerbate inflammation in the periodontium and intensify bone loss. Th17 cells are characterized by the expression of IL-17A and RORC2, that are the key factors aggravating inflammation and bone destruction with the plasticity between Tregs and Th17 cells determining the nature of the immune response. Furthermore, P. gingivalis infection was found to promote Th17/Treg imbalance by influencing T-cell differentiation.
Low Treg counts and suppressor function often accompany Th17-mediated autoimmunity, propagating inflammation and tissue destruction due to the Treg/Th17 cells imbalance. The Treg/Th17 ratio was found to gradually increase in experimental periodontitis induced in rats, from 0 to 8 weeks and the ratio was significantly increased in the peripheral circulation in various stages of periodontitis. In the 12th week, the number of Treg cells was higher than Th17 cells, thereby decreasing the ratio. However, the balance waved through the course of periodontitis may be correlated with the progression of the disease and the pathological tissue damage. On the contrary, Treg/Th17 imbalance was interpreted to be due to the lower Treg cell distribution in the human peripheral blood, and a higher number of Th17 cells in chronic periodontitis patients when compared to normal healthy controls. They also corresponded this observation to the conversion of Treg cells to pro-inflammatory phenotypes predominantly as Th17 cells due to a continuous low grade systemic inflammatory state., Thus, from these findings, it may be elucidated that when a large number of Tregs infiltrate into inflammatory sites, their peripheral count is reduced, and at the site of the inflammation, Th17 cells seem to comparatively outnumber Tregs cells. Moreover, when Treg function was inhibited using anti-GITR in mice with induced experimental periodontitis, there was increased inflammatory cell migration and alveolar bone loss.
| Tailoring Tregs to Treat Periodontitis|| |
Tregs are now being effectively used to prevent graft rejection, type 1 diabetes mellitus, lupus and auto-immune hepatitis due to their ability to be manipulated for adoptive-transfer purposes. Besides this, because of their immunosuppressive capabilities, they are used in immunotherapy. A group of systemically or locally delivered molecules such as cytokines, rapamycin, all trans-retinoic acid (ATRA), Vitamin D, and controlled Treg delivery systems are used to promote the proliferation, availability, functional, and phenotype stability.
In a study, ATRA, the most active metabolite of Vitamin A, was administered orally every other day in experimental periodontitis-induced mice. ATRA was shown to increase the differentiation of naive T-cells to Tregs, downregulate IL-17 expression, and upregulate IL-10 and TGF-β1, thus reducing alveolar bone resorption. In yet another study, Poly l-lactic acid (PLLA), nanofibrous spongy microspheres (NF-SMS), PLLA/polyethylene glycol (PEG) co-functionalized mesoporous silica nanoparticles (MSN), and poly lactic acid-co-glycolic acid microspheres (PLGA MS) were integrated and delivered as one vehicle for in situ Treg manipulation in a mouse model with periodontitis. MSNs and PLGA MS were shown to release miR-10a, essential for recruiting T-cells and IL-2/TGF-β1, essential for the differentiation of T cells into Tregs, while PLLA NF-SMS served as an injectable scaffold for the adhesion and proliferation of Treg cells. Thus, the system enriched the Treg cell-mediated immunity against alveolar bone loss. Usually, when the corresponding ligand, endogenous CCL22 binds with the receptor, chemoattraction, and active migration occur. Based on this concept, CCL22 releasing formulations when injected into murines and canines with induced experimental periodontitis, an increased migration of Treg cells to the site of inflammation occurs, thereby suppressing associated bone loss. Such a formulation would include IL-4, which is a Th2 chemokine, along with biodegradable polymers like PLGA for tuned release behavior. Once introduced, IL-4 promotes CCL22 expression and Treg cell migration and upregulates Th2 response., Such an interaction was even tested in recent studies and the CCL22/CCR4/IL-A axis was found to have a strong inhibitory response to the pro-inflammatory mediators, preventing their production and migration to the inflammatory site. Similarly, a mixture of factors such as IL-2, TGF-β, and rapamycin was effective in Treg induction at the sites of autoimmunity.
Treg cell therapies are proved to be one of the promising regenerative therapies for both hard and soft tissues by upregulating the pro-regenerative factors such as BMP4, BMP7, RUNX2, ALP, DMP1, and COL1A1. The availability of Tregs could be improved by culturing Dental Pulpal-Mesenchymal Stem Cells in vitro. The stem cells aid in the pooling of Tregs and enhancing immune homeostasis. In addition, an altered neutrophil rheostat could be beneficial, as both an increase and decrease of neutrophils can lead to a progressive IL-17-mediated inflammatory response. Although animal studies have shown desired results, the functional efficacy of Treg cell therapy to treat periodontitis in humans is yet to be explored.
| Future Directions of Tregs in Periodontics|| |
Among the CD4+ Treg cells, CD69+ Treg cells, a newer subset, was discovered recently and their percentage was inversely correlated with periodontal attachment loss. However, their counts were found to be increased in gingival tissues than in the peripheral blood. This could open a new avenue of therapy based on CD69+ Tregs. Another advent in Treg cell research is the expression of TNFR2 receptor, which has a tissue protective role mediated by Treg cells., Treg cytokine drugs like Tamibarotene (Am80) were found to reduce the osteoclast count, thereby decreasing the alveolar bone resorption.
Numerous vaccines are being developed against periodontal infections. One such vaccine is based on a heat shock protein, peptide 19, which was shown to stimulate CD4+ CD25+ FoxP3+ cells, thereby suppressing autoimmunity. The novel epitope spreader Pep19, could be targeted by human naive CD45RA+ Tregs for enhancing the expression of Tregs and their functions over effector T-cells by a process called linked suppression. Thus, Pep19-specific Tregs could be an effective molecular target for developing antigen-specific vaccinations to treat periodontitis. Heat shock protein 60 was also found to be beneficial in upregulating Tregs. Yet another study in mice with subcutaneous vaccination of P. gingivalis demonstrated a down regulation of Th17 cells and IL-17 A, thereby enhancing the action of Treg, RANKL + CD4+T cells, IL-10 and TGF-β1 production, resulting in a suppression of alveolar bone inflammation and destruction.
Adoptive cell therapy in combination with RNA-guided nuclease technology has strengthened and stabilized Treg-cell base cell therapies for various autoimmune diseases such as rheumatoid arthritis. This insight is developed using clustered regularly inter-spaced short palindromic repeats in combination with Cas 9 (an RNA-guided DNA enodonuclease enzyme) system. This system is promising to be a high-throughput technology to manufacture Chimeric Antigen Receptor Tregs to cure autoimmune diseases. This again may prove to be a new treatment option for periodontitis.
There is yet another entity of resident Treg cells in the gingival tissues, the CD8+ T cells, which are also gaining significance in suppressive immune responses. Future expanded studies and animal models with CD8+ cells may broaden their utility in immune therapy. A study on mice suggested that CCL22 when locally administered into the root canals, helped in regression of periapical lesion by manipulating chemoattraction of Tregs through CCL22/CCR4 axis, reducing the pro-inflammatory mediators.
Another novel approach would be modifying the migration of Treg cells for a targeted delivery by altering their homing capacity, proven by a study conducted on mice with intestinal inflammation by injecting specific homing-receptors, targeting Th1 inflamed sites.
| Limitations in Treg Therapy|| |
Despite the huge number of literature supporting the stability, yield and plasticity of Tregs generated in vitro, there is a lack of data on human trials. Major factors hindering such advancements could be the cost and the risks involved in these cell-based therapies, since they are in their nascent state of discoveries and developments. Human-based trials and further modifications to maintain their stability in vivo would encourage cell therapies to serve as a promising treatment for periodontitis.
| Conclusion|| |
With the advantages of cell therapies, Treg cell therapy would be a potent futuristic treatment option to address and treat periodontitis.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Goldstep F. Periodontal inflammation simplified. Oral Health J 2013:8-17.
Nisha S, Samyuktha GS, Shashikumar P, Chandra S. Periodontal disease – Historical and contemporary hypothesis: A review. SRM J Res Dent Sci 2017;8:121. [Full text]
Hajishengallis G, Lamont RJ. Beyond the red complex and into more complexity: The polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. Mol Oral Microbiol 2012;27:409-19.
Lamont RJ, Hajishengallis G. Polymicrobial synergy and dysbiosis in inflammatory disease. Trends Mol Med 2015;21:172-83.
Ebersole JL, Dawson DR 3rd
, Morford LA, Peyyala R, Miller CS, Gonzaléz OA. Periodontal disease immunology: 'Double indemnity' in protecting the host. Periodontol 2000 2013;62:163-202.
Cekici A, Kantarci A, Hasturk H, Van Dyke TE. Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontol 2000 2014;64:57-80.
Van Dyke TE, van Winkelhoff AJ. Infection and inflammatory mechanisms. J Clin Periodontol 2013;40 Suppl 14:S1-7.
Yucel-Lindberg T, Båge T. Inflammatory mediators in the pathogenesis of periodontitis. Expert Rev Mol Med 2013;15:e7.
Feng Z, Weinberg A. Role of bacteria in health and disease of periodontal tissues. Periodontol 2000 2006;40:50-76.
Hoeppli RE, Wu D, Cook L, Levings MK. The environment of regulatory T cell biology: Cytokines, metabolites, and the microbiome. Front Immunol 2015;6:61.
Mariano FS, Sardi JD, Duque C, Höfling JF, Gonçalves RB. The role of immune system in the development of periodontal disease: A brief review. Rev Odonto Ciência 2010;25:300-5.
Thornton AM. T regulatory cells. Curr Biol 2005;15:R582.
Zongyi Y, Dongying C, Baifeng L. Global regulatory T-cell research from 2000 to 2015: A bibliometric analysis. PLoS One 2016;11:e0162099.
Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133:775-87.
Zhao H, Liao X, Kang Y. Tregs: Where we are and what comes next? Front Immunol 2017;8:1578.
Garlet GP, Sfeir CS, Little SR. Restoring host-microbe homeostasis via selective chemoattraction of Tregs. J Dent Res 2014;93:834-9.
Garlet GP. Destructive and protective roles of cytokines in periodontitis: A re-appraisal from host defense and tissue destruction viewpoints. J Dent Res 2010;89:1349-63.
Cheng WC, Hughes FJ, Taams LS. The presence, function and regulation of IL-17 and Th17 cells in periodontitis. J Clin Periodontol 2014;41:541-9.
Adibrad M, Deyhimi P, Ganjalikhani Hakemi M, Behfarnia P, Shahabuei M, Rafiee L. Signs of the presence of Th17 cells in chronic periodontal disease. J Periodontal Res 2012;47:525-31.
Yang J, Wu J, Zhang R, Yao M, Liu Y, Miao L, et al
. Porphyromonas gingivalis
oral infection promote T helper 17/Treg imbalance in the development of atherosclerosis. J Dent Sci 2017;12:60-9.
Diller ML, Kudchadkar RR, Delman KA, Lawson DH, Ford ML. Balancing inflammation: The link between Th17 and regulatory T cells. Mediators Inflamm 2016;2016:6309219.
Gao L, Zhao Y, Wang P, Zhang L, Zhang C, Chen Q, et al
. Detection of Th17/Treg cells and related factors in gingival tissues and peripheral blood of rats with experimental periodontitis. Iran J Basic Med Sci 2017;20:294-300.
Indumathy P, Arun KV, Kumar TS, Raja A, Prashanth PS. Comparison of systemic levels of regulatory T cells in periodontal health and disease. J Dr NTR Univ Health Sci 2012;1:156.
Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H. The plasticity and stability of regulatory T cells. Nat Rev Immunol 2013;13:461-7.
Garlet GP, Cardoso CR, Mariano FS, Claudino M, de Assis GF, Campanelli AP, et al
. Regulatory T cells attenuate experimental periodontitis progression in mice. J Clin Periodontol 2010;37:591-600.
Alvarez C, Rojas C, Rojas L, Cafferata EA, Monasterio G, Vernal R. Regulatory T lymphocytes in periodontitis: A translational view. Mediators Inflamm 2018;2018:7806912.
Wang L, Wang J, Jin Y, Gao H, Lin X. Oral administration of all-trans retinoic acid suppresses experimental periodontitis by modulating the Th17/Treg imbalance. J Periodontol 2014;85:740-50.
Liu Z, Chen X, Zhang Z, Zhang X, Saunders L, Zhou Y, et al
. Nanofibrous spongy microspheres to distinctly release miRNA and growth factors to enrich regulatory T cells and rescue periodontal bone loss. ACS Nano 2018;12:9785-99.
Araujo-Pires AC, Vieira AE, Francisconi CF, Biguetti CC, Glowacki A, Yoshizawa S, et al
. IL-4/CCL22/CCR4 axis controls regulatory T-cell migration that suppresses inflammatory bone loss in murine experimental periodontitis. J Bone Miner Res 2015;30:412-22.
Glowacki AJ, Yoshizawa S, Jhunjhunwala S, Vieira AE, Garlet GP, Sfeir C, et al
. Prevention of inflammation-mediated bone loss in murine and canine periodontal disease via recruitment of regulatory lymphocytes. Proc Natl Acad Sci U S A 2013;110:18525-30.
Jhunjhunwala S, Balmert SC, Raimondi G, Dons E, Nichols EE, Thomson AW, et al
. Controlled release formulations of IL-2, TGF-β1 and rapamycin for the induction of regulatory T cells. J Control Release 2012;159:78-84.
Glowacki AJ, Gottardi R, Yoshizawa S, Cavalla F, Garlet GP, Sfeir C, et al
. Strategies to direct the enrichment, expansion, and recruitment of regulatory cells for the treatment of disease. Ann Biomed Eng 2015;43:593-602.
Hong JW, Lim JH, Chung CJ, Kang TJ, Kim TY, Kim YS, et al
. Immune tolerance of human dental pulp-derived mesenchymal stem cells mediated by CD4+ CD25+ FoxP3+ regulatory T-cells and induced by TGF-β1 and IL-10. Yonsei Med J 2017;58:1031-9.
Cortés-Vieyra R, Rosales C, Uribe-Querol E. Neutrophil functions in periodontal homeostasis. J Immunol Res 2016;2016:1396106.
Vitales-Noyola M, Martínez-Martínez R, Loyola-Rodríguez JP, Baranda L, Niño-Moreno P, González-Amaro R. Quantitative and functional analysis of CD 69+ T regulatory lymphocytes in patients with periodontal disease. J Oral Pathol Med 2017;46:549-57.
Tseng WY, Huang YS, Lin HH, Luo SF, McCann F, McNamee K, et al
. TNFR signalling and its clinical implications. Cytokine 2018;101:19-25.
Cohen JL, Wood KJ. TNFR2: The new Treg switch? Oncoimmunology 2017;7:e1373236.
Jin Y, Wang L, Liu D, Lin X. Tamibarotene modulates the local immune response in experimental periodontitis. Int Immunopharmacol 2014;23:537-45.
Choi JI, Seymour GJ. Vaccines against periodontitis: A forward-looking review. J Periodontal Implant Sci 2010;40:153-63.
Kim HJ, Cha GS, Joo JY, Lee J, Kim SJ, Lee J, et al
. Targeting the epitope spreader Pep19 by naïve human CD45RA+ regulatory T cells dictates a distinct suppressive T cell fate in a novel form of immunotherapy. J Periodontal Implant Sci 2017;47:292-311.
Brenu EW, Staines DR, Tajouri L, Huth T, Ashton KJ, Marshall-Gradisnik SM. Heat shock proteins and regulatory T cells. Autoimmune Dis 2013;2013:813256.
Wang L, Guan N, Jin Y, Lin X, Gao H. Subcutaneous vaccination with Porphyromonas gingivalis
ameliorates periodontitis by modulating Th17/Treg imbalance in a murine model. Int Immunopharmacol 2015;25:65-73.
Safari F, Farajnia S, Arya M, Zarredar H, Nasrolahi A. CRISPR and personalized Treg therapy: New insights into the treatment of rheumatoid arthritis. Immunopharmacol Immunotoxicol 2018;40:201-11.
Cardoso EM, Arosa FA. CD8+ T cells in chronic periodontitis: roles and rules. Front Immunol 2017;8:145.
Francisconi CF, Vieira AE, Biguetti CC, Glowacki AJ, Trombone AP, Letra A, et al
. Characterization of the protective role of regulatory T cells in experimental periapical lesion development and their chemoattraction manipulation as a therapeutic tool. J Endod 2016;42:120-6.
Hoeppli RE, MacDonald KN, Leclair P, Fung VC, Mojibian M, Gillies J, et al
. Tailoring the homing capacity of human Tregs for directed migration to sites of Th1-inflammation or intestinal regions. Am J Transplant 2019;19:62-76.
[Figure 1], [Figure 2]